Cargando…

Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience

AIM: SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population,...

Descripción completa

Detalles Bibliográficos
Autores principales: Littera, Roberto, Campagna, Marcello, Deidda, Silvia, Angioni, Goffredo, Cipri, Selene, Melis, Maurizio, Firinu, Davide, Santus, Simonetta, Lai, Alberto, Porcella, Rita, Lai, Sara, Rassu, Stefania, Scioscia, Rosetta, Meloni, Federico, Schirru, Daniele, Cordeddu, William, Kowalik, Marta Anna, Serra, Maria, Ragatzu, Paola, Carta, Mauro Giovanni, Del Giacco, Stefano, Restivo, Angelo, Deidda, Simona, Orrù, Sandro, Palimodde, Antonella, Perra, Roberto, Orrù, Germano, Conti, Maria, Balestrieri, Cinzia, Serra, Giancarlo, Onali, Simona, Marongiu, Francesco, Perra, Andrea, Chessa, Luchino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746644/
https://www.ncbi.nlm.nih.gov/pubmed/33343579
http://dx.doi.org/10.3389/fimmu.2020.605688
_version_ 1783624832739442688
author Littera, Roberto
Campagna, Marcello
Deidda, Silvia
Angioni, Goffredo
Cipri, Selene
Melis, Maurizio
Firinu, Davide
Santus, Simonetta
Lai, Alberto
Porcella, Rita
Lai, Sara
Rassu, Stefania
Scioscia, Rosetta
Meloni, Federico
Schirru, Daniele
Cordeddu, William
Kowalik, Marta Anna
Serra, Maria
Ragatzu, Paola
Carta, Mauro Giovanni
Del Giacco, Stefano
Restivo, Angelo
Deidda, Simona
Orrù, Sandro
Palimodde, Antonella
Perra, Roberto
Orrù, Germano
Conti, Maria
Balestrieri, Cinzia
Serra, Giancarlo
Onali, Simona
Marongiu, Francesco
Perra, Andrea
Chessa, Luchino
author_facet Littera, Roberto
Campagna, Marcello
Deidda, Silvia
Angioni, Goffredo
Cipri, Selene
Melis, Maurizio
Firinu, Davide
Santus, Simonetta
Lai, Alberto
Porcella, Rita
Lai, Sara
Rassu, Stefania
Scioscia, Rosetta
Meloni, Federico
Schirru, Daniele
Cordeddu, William
Kowalik, Marta Anna
Serra, Maria
Ragatzu, Paola
Carta, Mauro Giovanni
Del Giacco, Stefano
Restivo, Angelo
Deidda, Simona
Orrù, Sandro
Palimodde, Antonella
Perra, Roberto
Orrù, Germano
Conti, Maria
Balestrieri, Cinzia
Serra, Giancarlo
Onali, Simona
Marongiu, Francesco
Perra, Andrea
Chessa, Luchino
author_sort Littera, Roberto
collection PubMed
description AIM: SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinical outcome. METHOD AND MATERIALS: We recruited 619 healthy Sardinian controls and 182 SARS-CoV-2 patients. Thirty-nine patients required hospital care and 143 were without symptoms, pauci-symptomatic or with mild disease. For all participants, we collected demographic and clinical data and analyzed the HLA allele and haplotype frequencies. RESULTS: Male sex and older age were more frequent in hospitalized patients, none of whom had been vaccinated during the previous seasonal flu vaccination campaignes. Compared to the group of asymptomatic or pauci-symptomatic patients, hospitalized patients also had a higher frequency of autoimmune diseases and glucose-6-phosphate-dehydrogenase (G6PDH) deficiency. None of these patients carried the beta-thalassemia trait, a relatively common finding in the Sardinian population. The extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 [OR 0.1 (95% CI 0–0.6), Pc = 0.015] was absent in all 182 patients, while the HLA-C*04:01 allele and the three-loci haplotype HLA-A*30:02, B*14:02, C*08:02 [OR 3.8 (95% CI 1.8–8.1), Pc = 0.025] were more frequently represented in patients than controls. In a comparison between in-patients and home care patients, the HLA-DRB1*08:01 allele was exclusively present in the hospitalized patients [OR > 2.5 (95% CI 2.7–220.6), Pc = 0.024]. CONCLUSION: The data emerging from our study suggest that the extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 has a protective effect against SARS-CoV-2 infection in the Sardinian population. Genetic factors that resulted to have a negative influence on the disease course were presence of the HLA-DRB1*08:01 allele and G6PDH deficiency, but not the beta-thalassemic trait. Absence of influenza vaccination could be a predisposing factor for more severe disease.
format Online
Article
Text
id pubmed-7746644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77466442020-12-19 Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience Littera, Roberto Campagna, Marcello Deidda, Silvia Angioni, Goffredo Cipri, Selene Melis, Maurizio Firinu, Davide Santus, Simonetta Lai, Alberto Porcella, Rita Lai, Sara Rassu, Stefania Scioscia, Rosetta Meloni, Federico Schirru, Daniele Cordeddu, William Kowalik, Marta Anna Serra, Maria Ragatzu, Paola Carta, Mauro Giovanni Del Giacco, Stefano Restivo, Angelo Deidda, Simona Orrù, Sandro Palimodde, Antonella Perra, Roberto Orrù, Germano Conti, Maria Balestrieri, Cinzia Serra, Giancarlo Onali, Simona Marongiu, Francesco Perra, Andrea Chessa, Luchino Front Immunol Immunology AIM: SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinical outcome. METHOD AND MATERIALS: We recruited 619 healthy Sardinian controls and 182 SARS-CoV-2 patients. Thirty-nine patients required hospital care and 143 were without symptoms, pauci-symptomatic or with mild disease. For all participants, we collected demographic and clinical data and analyzed the HLA allele and haplotype frequencies. RESULTS: Male sex and older age were more frequent in hospitalized patients, none of whom had been vaccinated during the previous seasonal flu vaccination campaignes. Compared to the group of asymptomatic or pauci-symptomatic patients, hospitalized patients also had a higher frequency of autoimmune diseases and glucose-6-phosphate-dehydrogenase (G6PDH) deficiency. None of these patients carried the beta-thalassemia trait, a relatively common finding in the Sardinian population. The extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 [OR 0.1 (95% CI 0–0.6), Pc = 0.015] was absent in all 182 patients, while the HLA-C*04:01 allele and the three-loci haplotype HLA-A*30:02, B*14:02, C*08:02 [OR 3.8 (95% CI 1.8–8.1), Pc = 0.025] were more frequently represented in patients than controls. In a comparison between in-patients and home care patients, the HLA-DRB1*08:01 allele was exclusively present in the hospitalized patients [OR > 2.5 (95% CI 2.7–220.6), Pc = 0.024]. CONCLUSION: The data emerging from our study suggest that the extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 has a protective effect against SARS-CoV-2 infection in the Sardinian population. Genetic factors that resulted to have a negative influence on the disease course were presence of the HLA-DRB1*08:01 allele and G6PDH deficiency, but not the beta-thalassemic trait. Absence of influenza vaccination could be a predisposing factor for more severe disease. Frontiers Media S.A. 2020-12-04 /pmc/articles/PMC7746644/ /pubmed/33343579 http://dx.doi.org/10.3389/fimmu.2020.605688 Text en Copyright © 2020 Littera, Campagna, Deidda, Angioni, Cipri, Melis, Firinu, Santus, Lai, Porcella, Lai, Rassu, Scioscia, Meloni, Schirru, Cordeddu, Kowalik, Serra, Ragatzu, Carta, Del Giacco, Restivo, Deidda, Orrù, Palimodde, Perra, Orrù, Conti, Balestrieri, Serra, Onali, Marongiu, Perra and Chessa http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Littera, Roberto
Campagna, Marcello
Deidda, Silvia
Angioni, Goffredo
Cipri, Selene
Melis, Maurizio
Firinu, Davide
Santus, Simonetta
Lai, Alberto
Porcella, Rita
Lai, Sara
Rassu, Stefania
Scioscia, Rosetta
Meloni, Federico
Schirru, Daniele
Cordeddu, William
Kowalik, Marta Anna
Serra, Maria
Ragatzu, Paola
Carta, Mauro Giovanni
Del Giacco, Stefano
Restivo, Angelo
Deidda, Simona
Orrù, Sandro
Palimodde, Antonella
Perra, Roberto
Orrù, Germano
Conti, Maria
Balestrieri, Cinzia
Serra, Giancarlo
Onali, Simona
Marongiu, Francesco
Perra, Andrea
Chessa, Luchino
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title_full Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title_fullStr Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title_full_unstemmed Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title_short Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
title_sort human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to sars-cov-2 infection and severity of the disease course. the sardinian experience
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746644/
https://www.ncbi.nlm.nih.gov/pubmed/33343579
http://dx.doi.org/10.3389/fimmu.2020.605688
work_keys_str_mv AT litteraroberto humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT campagnamarcello humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT deiddasilvia humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT angionigoffredo humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT cipriselene humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT melismaurizio humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT firinudavide humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT santussimonetta humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT laialberto humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT porcellarita humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT laisara humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT rassustefania humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT sciosciarosetta humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT melonifederico humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT schirrudaniele humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT cordedduwilliam humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT kowalikmartaanna humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT serramaria humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT ragatzupaola humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT cartamaurogiovanni humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT delgiaccostefano humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT restivoangelo humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT deiddasimona humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT orrusandro humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT palimoddeantonella humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT perraroberto humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT orrugermano humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT contimaria humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT balestriericinzia humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT serragiancarlo humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT onalisimona humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT marongiufrancesco humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT perraandrea humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience
AT chessaluchino humanleukocyteantigencomplexandotherimmunogeneticandclinicalfactorsinfluencesusceptibilityorprotectiontosarscov2infectionandseverityofthediseasecoursethesardinianexperience